Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

NCT04501679 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT04501679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04501679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Lead sponsor
Galderma R&D
Phase
Phase 3
Overall status
Completed
Start date
August 11, 2020
Completion date
March 31, 2022
Enrollment
274 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis